MEI Pharma Inc MEIP
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if MEIP is a good fit for your portfolio.
News
-
MEI Pharma Board of Directors Aligns on Strategy to Advance Voruciclib and ME-344
-
MEI Pharma Reports Initial Data from Clinical Study Evaluating ME-344 in Combination with Bevacizumab (Avastin®) in Relapsed Metastatic Colorectal Cancer Patients
-
MEI Pharma to Present at the Stifel 2024 Virtual Targeted Oncology Forum
-
MEI Pharma Reports Update from Clinical Study Evaluating Oral CDK9 Inhibitor Voruciclib in Combination with Venetoclax in Patients with Relapsed and Refractory Acute Myeloid Leukemia
-
Glancy Prongay & Murray LLP Announces Investigation of MEI Pharma, Inc. (MEIP)
-
MEI Pharma Reports Second Quarter Fiscal Year 2024 Results and Operational Highlights
Trading Information
- Previous Close Price
- $3.31
- Day Range
- $3.25–3.38
- 52-Week Range
- $3.20–7.97
- Bid/Ask
- $3.30 / $3.35
- Market Cap
- $21.65 Mil
- Volume/Avg
- 12,047 / 23,148
Key Statistics
- Price/Earnings (Normalized)
- 1.14
- Price/Sales
- 0.30
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
MEI Pharma Inc is focused on the clinical development of novel therapies for cancer. The company's clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes Zandelisib, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with recurrent chronic lymphocytic leukemia or follicular non-Hodgkin's lymphoma; and ME-344, an isoflavone-based mitochondrial inhibitor for the treatment of HER2-negative breast cancer and Pracinostat, an oral histone deacetylase inhibitor. Geographically, all the business activities function through the region of the United States.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 46
- Website
- https://www.meipharma.com
Valuation
|
Metric
|
MEIP
|
|---|---|
Price/Earnings (Normalized) | 1.14 |
Price/Book Value | 0.36 |
Price/Sales | 0.30 |
Price/Cash Flow | 0.88 |
Price/Earnings
MEIP
Financial Strength
|
Metric
|
MEIP
|
|---|---|
Quick Ratio | 7.40 |
Current Ratio | 8.23 |
Interest Coverage | — |
Quick Ratio
MEIP
Profitability
|
Metric
|
MEIP
|
|---|---|
Return on Assets (Normalized) | 19.02% |
Return on Equity (Normalized) | 44.64% |
Return on Invested Capital (Normalized) | 30.49% |
Return on Assets
MEIP
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Zrclzgdy | Kwjxf | $553.3 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Xsfvfgm | Xyzhqv | $101.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Ndtjydpg | Qlllfb | $98.1 Bil | |
MRNA
| Moderna Inc | Pfprsrc | Chj | $39.7 Bil | |
ARGX
| argenx SE ADR | Ybbhtrv | Lhy | $21.7 Bil | |
BNTX
| BioNTech SE ADR | Ttjrcpwfk | Zkq | $20.8 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Ftylhlgk | Gybjgh | $18.3 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Ggvyjcp | Stzzmj | $17.1 Bil | |
RPRX
| Royalty Pharma PLC Class A | Bfktyfsmv | Fxwwjxv | $12.5 Bil | |
INCY
| Incyte Corp | Cnhzxzjg | Hxfsfq | $11.8 Bil |